Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Stock OTC Markets
Stocks
SFOSF
CNE100001M79
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
14:49:06 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 2.200 USD | +3.77% |
|
+12.82% | -12.00% |
| 08-14 | Fosun Pharma Starts Phase Two Trial for COPD Drug | MT |
| 08-09 | Fosun Pharma Secures China Approval for Two Drugs | MT |
| Market Cap | 57.36B 8.52B 7.31B 6.83B 6.26B 11.78B 814B 11.97B 80.54B 31.54B 408B 32B 31.3B 1,351B | P/E 2026 * |
16x | P/E 2027 * | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 70.33B 10.45B 8.96B 8.37B 7.68B 14.44B 999B 14.67B 98.74B 38.66B 501B 39.23B 38.37B 1,656B | EV / Sales 2026 * |
1.62x | EV / Sales 2027 * | 1.59x |
| Free-Float |
62.77% | Yield 2026 * |
1.94% | Yield 2027 * | 2.18% |
| 1 day | +3.77% | ||
| 1 week | +12.82% | ||
| 3 months | -9.28% | ||
| 6 months | -15.71% | ||
| Current year | -12.00% |
| 1 week | 2.12 |  | 2.2 |
| 1 month | 1.95 | | 2.2 |
| Current year | 1.95 | | 2.86 |
| 1 year | 1.95 | | 3.5 |
| 3 years | 1.5 | | 3.5 |
| 5 years | 1.5 | | 7.24 |
| 10 years | 0 | | 10 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Liu
CEO | Chief Executive Officer | 50 | 2025-06-23 |
Zhi Huang
DFI | Director of Finance/CFO | - | 2026-04-01 |
Wen Jie Zhang
PSD | President | 59 | 2023-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
CHM | Chairman | 54 | 1994-03-31 |
Yi Liu
BRD | Director/Board Member | 50 | 2025-12-01 |
Dong Hui Pan
BRD | Director/Board Member | 56 | 2020-06-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.77% | +12.82% | - | - | 8.64B | |
| +4.46% | +4.92% | +82.07% | +134.31% | 1,093B | |
| +0.85% | +4.81% | +53.77% | +58.51% | 653B | |
| +2.72% | +6.92% | +28.99% | +77.15% | 458B | |
| +1.80% | +0.52% | +41.20% | +44.05% | 355B | |
| +1.24% | +2.35% | +25.99% | +42.21% | 294B | |
| +2.07% | +2.97% | +2.27% | +13.06% | 248B | |
| +4.02% | +6.29% | +49.67% | +68.96% | 230B | |
| +1.05% | -0.02% | -13.96% | -52.13% | 203B | |
| +2.90% | +8.63% | +25.11% | +94.52% | 178B | |
| Average | +2.11% | +3.13% | +32.79% | +53.40% | 412.27B | |
| Weighted average by Cap. | +1.53% | +3.65% | +46.87% | +73.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 43.31B 6.43B 5.52B 5.15B 4.73B 8.89B 615B 9.04B 60.81B 23.81B 308B 24.16B 23.63B 1,020B | 43.93B 6.53B 5.6B 5.23B 4.8B 9.02B 624B 9.17B 61.68B 24.15B 313B 24.5B 23.97B 1,034B |
| Net income | 3.92B 582M 499M 466M 428M 804M 55.61B 817M 5.5B 2.15B 27.89B 2.18B 2.14B 92.22B | 4.32B 641M 550M 514M 471M 886M 61.3B 901M 6.06B 2.37B 30.74B 2.41B 2.36B 102B |
| Net Debt | 12.96B 1.93B 1.65B 1.54B 1.41B 2.66B 184B 2.7B 18.2B 7.13B 92.3B 7.23B 7.07B 305B | 13.01B 1.93B 1.66B 1.55B 1.42B 2.67B 185B 2.71B 18.26B 7.15B 92.62B 7.25B 7.1B 306B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-19 | US$2.200 | +3.77% | 430 |
| 26-08-18 | US$2.120 | +8.72% | 1,675 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 600196 Stock
- SFOSF Stock
Select your edition
All financial news and data tailored to specific country editions
